Linezolid Accord (Linezolid)

• Linezolid is an oxazolidinone antibiotic used to treat serious Gram‑positive bacterial infections.
• Skin and soft tissue infections: achieves clinical cure and microbiological eradication of infections such as cellulitis, abscesses, and wound infections caused by susceptible Gram‑positive bacteria.
• Pneumonia: provides effective therapy for hospital‑acquired or community‑acquired pneumonia caused by MRSA or other susceptible Gram‑positive pathogens, improving respiratory outcomes.
• Infections caused by susceptible Gram‑positive bacteria (e.g., MRSA, VRE): delivers bacteriostatic inhibition of protein synthesis to clear systemic or localized infections where other agents may fail.

• Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. This interaction prevents the formation of the initiation complex, thereby blocking the translation of mRNA into essential proteins. The resulting bacteriostatic effect halts growth of susceptible Gram‑positive organisms, including MRSA and VRE, allowing the host immune system to eradicate the infection and reduces bacterial proliferation at the infection site.

Linezolid may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Nausea: mild gastrointestinal upset.
• Diarrhea: loose stools.
• Headache: transient cranial discomfort.
• Thrombocytopenia: mild reduction in platelet count.

Serious or Rare Side Effects

• Myelosuppression: severe decrease in blood cell production.
• Peripheral neuropathy: nerve damage causing numbness or tingling.
• Lactic acidosis: accumulation of lactate leading to metabolic acidosis.

When prescribing Linezolid, clinicians should observe several precautionary measures to ensure patient safety.

• Renal impairment: adjust monitoring as the drug is excreted unchanged and may accumulate.
• Hepatic dysfunction: use with caution in patients with liver disease due to potential metabolism changes.
• Hematologic monitoring: perform regular complete blood counts to detect thrombocytopenia or anemia.
• Serotonergic agents: avoid concomitant use with MAO inhibitors or SSRIs because of risk of serotonin syndrome.
• Pregnancy and lactation: use only if the potential benefit justifies the potential risk, as safety data are limited.
• Store at room temperature: keep the solution below 25°C, protect from light and moisture, and retain in the original container.

Linezolid can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid)

• MAO inhibitors: concurrent use may precipitate severe hypertension or serotonin syndrome.
• SSRIs, SNRIs, Tricyclic antidepressants: increase risk of serotonin syndrome.
• Rifampicin: may reduce linezolid plasma concentrations, decreasing effectiveness.

Moderate Interactions (Monitor Closely)

• Warfarin: linezolid may enhance anticoagulant effect, requiring INR monitoring.
• Cycloserine: combined use may increase risk of peripheral neuropathy.
• Ethanol: may potentiate disulfiram‑like reactions, causing flushing and nausea.